Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
- Authors: Shorokhova P.B.1, Baranov V.L1, Vorokhobina N.V1, Shpilevaya O.S1
-
Affiliations:
- North-Western State Medical University n.a. I.I. Mechnikov
- Issue: Vol 26, No 4 (2019)
- Pages: 10-16
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/297933
- DOI: https://doi.org/10.18565/pharmateca.2019.4.10-16
- ID: 297933
Cite item
Abstract
Full Text
About the authors
Polina B. Shorokhova
North-Western State Medical University n.a. I.I. Mechnikov
Email: poliamina@gmail.com
Department of Endocrinology n.a. Acad. V.G. Baranov, Postgraduate Student St. Petersburg, Russia
V. L Baranov
North-Western State Medical University n.a. I.I. MechnikovDepartment of Endocrinology n.a. Acad. V.G. Baranov St. Petersburg, Russia
N. V Vorokhobina
North-Western State Medical University n.a. I.I. MechnikovDepartment of Endocrinology n.a. Acad. V.G. Baranov St. Petersburg, Russia
O. S Shpilevaya
North-Western State Medical University n.a. I.I. MechnikovDepartment of Endocrinology n.a. Acad. V.G. Baranov St. Petersburg, Russia
References
- DeFronzo R.A. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diab. 2009;58(4):773-95. doi: 10.2337/db09-9028.
- Schwartz S.S., Epstein S., Corkey B.E., et al. The time is right for a new classification system for diabetes: rationale and implications of the ß-cell-centric classification schema. Diab Care. 2016;39(2):179-86. doi: 10.2337/dc15-1585.
- Аметов А.С. Патофизиологический подход как основа выбора стратегии успешного лечения сахарного диабета 2 типа. Фарматека. 2017;5:28-35.
- Brunetti A, Chiefari E., Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diab. 2014;5(2):128-40. Doi: 10.4239/ wjd.v5.i2.128.
- Sun X., Yu W., Hu C. Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. Biomed Res int. 2014;2014:926713. doi: 10.1155/2014/926713.
- Billings L.K., Florez J.C. The genetics of type 2 diabetes: what have we learned from GWAS? Ann NX. Acad Sci. 2010;1212(1):59-77. doi: 10.1111/j.1749-6632.2010.05838.x.
- Singh S., Usman K., Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diab. 2016;7(15):302-15. doi: 10.4239/wjd. v7.i15.302.
- Hattersley A.T. Prime suspect: the TCF7L2 gene and type 2 diabetes risk. J. Clin Invest. 2007;117(8):2077-79. doi: 10.1172/JCI33077.
- Lyssenko V., Lupi R., Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 2007;117(8):2155-63. Doi: 10.1172/ JCI30706.
- Zhou Y., Park S.Y., Su J., et al. TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet. 2014;23(24):6419-31. doi: 10.1093/hmg/ddu359.
- Cauchi S., Meyre D., Dina C., et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diab. 2006;55(10):2903-908. Doi: 10.2337/ db06-0474.
- Saxena R., Gianniny L., Burtt N.P, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diab. 2006;55(10):2890-95. Doi: 10,2337/db06-0381.
- Aguilar-Bryan L., Bryan J. Molecular biology of adenosine triphosphate - sensitive potassium channels. Endocr. Rev. 1999;20(2):101-35. doi: 10.1210/edrv.20.2.0361.
- Seino S., Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003;81(2):133-76. Doi:10.1016/ S0079-6107(02)00053-6.
- Schwanstecher C., Meyer U., Schwanstecher M. KIR6.2 Polymorphism Predisposes to Type 2 Diabetes by Inducing Overactivity of Pancreatic-CellATP-Sensitive K+ Channels. Diab. 2002;51(3): 875-79. doi: 10.2337/diabetes.51.3.875.
- Mongolian population. J Diab. 2012;4(3): 238-42. doi: 10.1111/j.1753-0407.2011.00177.
- Sanghera D.K., Ortega L., Han S., et al. Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC. Med Genet. 2008;9(1):59. doi: 10.1186/1471-2350-9-59.
- Yang L., Zhou X., Luo Y, et al. Association between KCNJ11 gene polymorphisms and risk of type 2 diabetes mellitus in East Asian populations: a meta-analysis in 42,573 individuals. Mol Biol Rep. 2012;39(1): 645-59. doi: 10.1007/s11033- 011-0782-6.
- Hamming K.S.C., Soliman D., Matemisz L.C., et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diab. 2009;58(10):2419-24. Doi: 10.2337/ db09-0143.
- Florez J.C., Burtt N., de Bakker P.I.W., et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diab. 2004;53(5):1360-68. Doi: 10.2337/ diabetes.53.5.1360.
- Sokolova E.A., Bondar I.A., Shabelnikova O.Y, et al. Replication of KCNJ11 (p.E23K) and ABCC8 (p.S1369A) Association in Russian Diabetes Mellitus 2 Type Cohort and Meta-Analysis. PLoS. One. 2015;10(5):e0124662. Published 2015 May 8. doi: 10.1371/journal.pone.0124662.
- Inzucchi S.E., McGuire D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulat. 2008;117(4):574-84. doi: 10.1161/CIRCULATIONAHA.107.735 795.
- Chacra A.R., Tan G.H., Apanovitch A., et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin. Pract. 2009;63(9):1395-406. doi: 10.1111/j.1742-1241.2009.02143.
- Aschner P, Chan J., Owens D.R., et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262-69. doi: 10.1016/S0140-6736(12)60439-5.
- Aso Y., Ozeki N., Terasawa T., et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res. 2012;159(1):25-31. Doi: 10.1016/j. trsl.2011.09.005.
- Xiong X., Shao W., Jin T. New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic ß-cells: the involvement of the Wnt signaling pathway effector ß-catenin. Islets. 2012;4(6):359-65. doi: 10.4161/isl.23345
- Zimdahl H., Ittrich C., Graefe-Mody U., et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetol. 2014;57(9):1869-75. doi: 10.1007/s00125-014-3276-y.
- da Silva Xavier G., Mondragon A., Sun G., et al. Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetol. 2012;55(10):2667-76. doi: 10.1007/s00125- 012-2600-7.
- Shu L., Matveyenko A.V, Kerr-Conte J., et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 2009;18(13):2388-99. doi: 10.1093/hmg/ddp178.
- Loos R.J., Franks P.W., Francis R.W., et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diab. 2007;56(7):1943-47. Doi: 10.2337/ db07-0055.
- Ordelheide A.M., Gerst F., Rothfuss O., et al. Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion. Mol Metab. 2013;2(3):243-55.
- Weyrich P, Staiger H., Stancakova A., et al. Common polymorphisms within the NR4A3 locus, encoding the orphan nuclear receptor Nor-1, are associated with enhanced beta-cell function in non-diabetic subjects. BMC. Med Genet. 2009;10(1):77. doi: 10.1186/1471-2350-10-77.
- Hart L.M., Fritsche A., Nijpels G., et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diab. 2013;62(9):3275-81. doi: 10.2337/db13-0227.
- Jamaluddin J.L., Huri H.Z., Vethakkan S.R. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016;17(8):867-81. doi: 10.2217/pgs-2016-0010.
- McTaggart J.S., Clark R.H., Ashcroft F.M. The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J. Physiol. 2010;588(17):3201-209. Doi: 10.1113/ jphysiol.2010.191767.
- Sesti G., Laratta E., Cardellini M., et al. The E23K variant of KCNJ11 encoding the pancreatic betacell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(6):2334-39. Doi: 10.1210/ jc.2005-2323.
- Holstein A., Hahn M., Stumvoll M., et al. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009;41(5):387-90. doi: 10.1055/s-0029-1192019.
- El-Sisi A.E., Hegazy S.K., Metwally S.S., et al. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes. Ther Adv. Endocrinol Metab. 2011;2(4):155-64. doi: 10.1177/2042018811415985.
- Shimajiri Y., Yamana A., Morita S., et al. Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non-obese patient with type 2 diabetes. J Diab Invest. 2013;4(5):445-49. doi: 10.1111/jdi.12070.
- Feng Y., Mao G., Ren X., et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diab Care. 2008;31(10):1939-44. doi: 10.2337/dc07-2248.
- Javorsky M., Klimcakova L., Schroner Z., et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012;23(3): 245-49. Doi: 10.1016/j. ejim.2011.10.018.
- Li Q., Chen M., Zhang R., et al. KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2014;41(10):748-54. doi: 10.1111/1440-1681.
- Gloyn A.L., Hashim Y., Ashcroft S.J., et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diab Med. 2001;18(3):206-doi: 10.1046/j.1464-5491.2001. 00449.
- Nikolac N., Simundic A.M., Katalinic D., et al. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 2009;40(5):387-92. Doi: 10.1016/j. arcmed.2009.06.006.
- Ragia G., Tavridou A., Petridis I., et al. Association of KCNJ11E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diab Res. Clin Pract. 2012;98(1):119-24. Doi: 10.1016/j. diabres.2012.04.017.
- Klen J., Dolzan V., Janez A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol. 2014;70(4):421-doi: 10.1007/s00228-014-1641.
- Zhang H., Liu X., Kuang H., et al. Association of sulfonylurea receptor 1genotype with therapeutic response to gliclazide in type 2 diabetes. Diab Res Clin Pract. 2007;77(1):58-61. Doi: 10.1016/j. diabres.2006.10.021.
- Sato R., Watanabe H., Genma R., et al. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogen. 2010;11(12):1743-50. Doi: 10.2217/ pgs.10.135.
- Nikolac N., Simundic A.M., Saracevic A., et al. ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy. Genet Test Mol Biomark. 2012;16(8):924-30. Doi:10.1089/ gtmb.2011.0337.
- Meirhaeghe A., Helbecque N., Cottel D., et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet. 2001;101(1):4-8. Doi:10.1002/ ajmg.1297.
- Zychma M.J., Gumprecht J., Strojek K., et al. Sulfonylurea receptor gene 16-3 polymorphism -association with sulfonylurea or insulin treatment in type 2 diabetic subjects. Med Sci Monit. 2002;8(7):512-15.
- Pearson E.R., Donnelly L.A., Kimber C., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diab. 2007;56(8):2178-82. Doi:10.2337/ db07-0440.
- Holstein A, Hahn M., Körner A, et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC. Med Genet. 2011;12(1):30. doi: 10.1186/1471-2350-12-30.
- Schroner Z, Javorsky M., Tkacova R., et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diab Obes Metab. 2011;13(1):89-91. doi: 10.1111/j.1463-1326.2010.01324.